As Jazz Pharmaceuticals Plc (JAZZ) Stock Price Rose, Shareholder Jaffetilchin Investment Partners Has Cut Position; Amgen (AMGN) Holder Smead Capital Management Decreased Stake

January 14, 2018 - By wolcottdaily

Smead Capital Management Inc decreased its stake in Amgen Inc (AMGN) by 1.32% based on its latest 2017Q3 regulatory filing with the SEC. Smead Capital Management Inc sold 9,547 shares as the company’s stock declined 9.68% while stock markets rallied. The institutional investor held 712,902 shares of the biological products (no diagnostic substances) company at the end of 2017Q3, valued at $132.92 million, down from 722,449 at the end of the previous reported quarter. Smead Capital Management Inc who had been investing in Amgen Inc for a number of months, seems to be less bullish one the $134.32 billion market cap company. The stock increased 1.69% or $3.08 during the last trading session, reaching $185.04. About 3.11M shares traded or 13.64% up from the average. Amgen Inc. (NASDAQ:AMGN) has risen 5.27% since January 14, 2017 and is uptrending. It has underperformed by 11.43% the S&P500.

Jaffetilchin Investment Partners Llc decreased its stake in Jazz Pharmaceuticals Plc (JAZZ) by 41.34% based on its latest 2017Q3 regulatory filing with the SEC. Jaffetilchin Investment Partners Llc sold 3,952 shares as the company’s stock rose 8.72% with the market. The institutional investor held 5,607 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $820,000, down from 9,559 at the end of the previous reported quarter. Jaffetilchin Investment Partners Llc who had been investing in Jazz Pharmaceuticals Plc for a number of months, seems to be less bullish one the $9.00B market cap company. The stock increased 1.14% or $1.69 during the last trading session, reaching $150.19. About 797,526 shares traded or 64.80% up from the average. Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) has risen 1.25% since January 14, 2017 and is uptrending. It has underperformed by 15.45% the S&P500.

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on February, 1. They expect $3.02 EPS, up 4.50% or $0.13 from last year’s $2.89 per share. AMGN’s profit will be $2.19 billion for 15.32 P/E if the $3.02 EPS becomes a reality. After $3.27 actual EPS reported by Amgen Inc. for the previous quarter, Wall Street now forecasts -7.65% negative EPS growth.

Among 24 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 13 Hold. Therefore 46% are positive. Amgen Inc. had 74 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Amgen Inc. (NASDAQ:AMGN) has “Neutral” rating given on Friday, July 29 by Citigroup. The rating was maintained by Oppenheimer on Wednesday, August 23 with “Buy”. On Wednesday, November 1 the stock rating was downgraded by Argus Research to “Hold”. UBS maintained Amgen Inc. (NASDAQ:AMGN) on Wednesday, July 26 with “Neutral” rating. The stock has “Neutral” rating by Citigroup on Wednesday, September 28. The firm has “Equal-Weight” rating given on Friday, October 13 by Barclays Capital. Oppenheimer maintained the shares of AMGN in report on Tuesday, June 13 with “Buy” rating. Credit Suisse downgraded the shares of AMGN in report on Tuesday, December 20 to “Neutral” rating. Mizuho maintained the shares of AMGN in report on Friday, July 14 with “Buy” rating. As per Thursday, September 7, the company rating was maintained by Piper Jaffray.

Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.16, from 1.15 in 2017Q2. It fall, as 58 investors sold AMGN shares while 511 reduced holdings. 108 funds opened positions while 453 raised stakes. 555.05 million shares or 0.41% less from 557.32 million shares in 2017Q2 were reported. Nottingham Advsrs has invested 0.05% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Cannell Peter B And Company holds 8,535 shares. Wellington Management Llp reported 0.27% stake. Moreover, Schroder Mngmt Gp has 0.79% invested in Amgen Inc. (NASDAQ:AMGN). Denver Advsr Ltd Co invested 0.87% of its portfolio in Amgen Inc. (NASDAQ:AMGN). 15,656 were accumulated by Heritage Wealth Advsrs. Hamilton Point Advsrs Limited Liability Corp holds 22,635 shares. Dowling And Yahnke Limited Liability Company holds 0.72% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 38,131 shares. Fincl Bank Of Montreal Can holds 2.68 million shares or 0.46% of its portfolio. Greystone Invest Management Limited owns 1,600 shares. The Wisconsin-based Dana Invest Advisors Inc has invested 1.41% in Amgen Inc. (NASDAQ:AMGN). Vanguard Gru reported 52.51M shares. Dnb Asset As invested in 0.19% or 75,866 shares. Whalerock Point Limited Liability has invested 0.49% in Amgen Inc. (NASDAQ:AMGN). World Asset Management Incorporated has invested 0.42% in Amgen Inc. (NASDAQ:AMGN).

Since October 9, 2017, it had 0 insider buys, and 2 sales for $553,240 activity.

Investors sentiment decreased to 1.03 in 2017 Q3. Its down 0.36, from 1.39 in 2017Q2. It dived, as 39 investors sold JAZZ shares while 82 reduced holdings. 31 funds opened positions while 94 raised stakes. 53.58 million shares or 3.54% more from 51.74 million shares in 2017Q2 were reported. Hutchin Hill Capital Ltd Partnership reported 8,375 shares. Cadian Mngmt Lp holds 8.07% or 1.18 million shares in its portfolio. Sei Invs holds 10,418 shares. Rice Hall James & Assoc Limited Liability Co has 18,459 shares. Deutsche Financial Bank Ag has 0.02% invested in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) for 236,434 shares. World Asset Mgmt has 0.01% invested in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) for 1,451 shares. Envestnet Asset Management accumulated 1,004 shares. Advisors Asset Management Incorporated reported 16,331 shares or 0.04% of all its holdings. 300 are held by Hillsdale Mngmt Inc. Tealwood Asset Management has 18,837 shares for 0.99% of their portfolio. Clarivest Asset Mgmt Ltd reported 0.01% stake. Livforsakringsbolaget Skandia Omsesidigt holds 0.33% or 24,980 shares in its portfolio. 1.67 million were reported by Jpmorgan Chase And Communications. Jane Street Group Incorporated Ltd stated it has 2,569 shares or 0% of all its holdings. Amp Investors Ltd accumulated 22,933 shares.

Since August 10, 2017, it had 0 insider purchases, and 16 insider sales for $2.80 million activity. $102,077 worth of stock was sold by McSharry Heather Ann on Thursday, August 10. RIEDEL NORBERT G had sold 662 shares worth $94,248. On Monday, December 11 the insider ENRIGHT PATRICK G sold $1.26M. Another trade for 1,000 shares valued at $153,520 was sold by COZADD BRUCE C. Another trade for 662 shares valued at $94,248 was sold by O’Keefe Kenneth W. Another trade for 717 shares valued at $102,078 was made by Gray Peter on Thursday, August 10.

Among 21 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Jazz Pharmaceuticals had 70 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by SunTrust on Thursday, June 2 with “Buy”. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, June 27 report. The firm earned “Buy” rating on Wednesday, October 18 by FBR Capital. Wells Fargo maintained the stock with “Buy” rating in Wednesday, November 8 report. Mizuho maintained Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) on Wednesday, May 31 with “Hold” rating. RBC Capital Markets maintained the shares of JAZZ in report on Thursday, September 14 with “Buy” rating. Mizuho maintained the shares of JAZZ in report on Tuesday, February 21 with “Buy” rating. The firm has “Buy” rating by UBS given on Wednesday, May 11. The firm earned “Neutral” rating on Tuesday, November 10 by Mizuho. As per Wednesday, February 24, the company rating was maintained by Mizuho.

Analysts await Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) to report earnings on February, 27. They expect $2.63 earnings per share, up 37.70% or $0.72 from last year’s $1.91 per share. JAZZ’s profit will be $157.67 million for 14.28 P/E if the $2.63 EPS becomes a reality. After $2.93 actual earnings per share reported by Jazz Pharmaceuticals Public Limited Company for the previous quarter, Wall Street now forecasts -10.24% negative EPS growth.

Jaffetilchin Investment Partners Llc, which manages about $401.38M and $424.32 million US Long portfolio, upped its stake in Royce Micro (NYSE:RMT) by 84,818 shares to 138,034 shares, valued at $1.30 million in 2017Q3, according to the filing. It also increased its holding in Vanguard Index Fds (VTI) by 76,357 shares in the quarter, for a total of 231,441 shares, and has risen its stake in Ishares Tr (IJH).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts